[Comparison between pathological findings and MR diffusion-weighted imaging in primary hepatocellular carcinoma after transcatheter arterial chemoembolization].
OBJECTIVE
To explore the pathological basis of diffusion-weighted imaging (DWI) findings in hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE).


METHODS
DWI was performed in 15 patients with HCC treated by TACE within 24 - 48 hours before II-phase operation. The DWI findings of the liver lesions were analyzed and correlated with pathological findings including macroscopic observation, HE staining and immunohistochemical staining for bFGF.


RESULTS
(1) The viable tumor area showed mostly hypersignal intensity (12/15), whereas coagulative necrotic lesions showed hyposignal (8/15) or isosignal intensity (6/15). The ADC values of zones of viable tumor and necrosis in tumor were (1.42 +/- 0.16) x 10(-3) mm(2)/s and (1.58 +/- 0.18) x 10(-3) mm(2)/s, respectively. There was a significant difference of ADC values between the two zones (t = 2.618, P < 0.05). (2) There was a significant difference in ADC values of viable tumor between well and poorly differentiated tumors (t = -2.646, P < 0.05). The distinction of ADC values of the whole tumor was significant among tumors with different degree of necrosis (chi(2) = 7.236, P < 0.05). (3) A negative correlation was observed between bFGF protein expression index and ADC values of viable parts of the tumors in the study group (r = -0.552, P = 0.033).


CONCLUSIONS
DWI shows certain characteristic features of the HCC after TACE, and can be used to distinguish viable and necrotic tumor tissues in HCC after TACE.
Xiao
Yun-Ping
YP
Department of Radiology, The 2nd Xiangya Hospital, Central South University, Changsha 410011, China.
Xiao
En-Hua
EH
Luo
Jian-Guang
JG
Bian
Du-Jun
DJ
Li
Mo-Qiu
MQ
He
Zhong
Z
Shang
Quan-Liang
QL
Liang
Bin
B
D000293:Adolescent; D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007459:Iodized Oil / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D055815:Young Adult
D016222:Fibroblast Growth Factor 2; D016685:Mitomycin; D007459:Iodized Oil; D002945:Cisplatin; D005472:Fluorouracil